Lista de obras - Nicolas Boissel - Dominio Público Uruguay

A landscape of germline mutations in a cohort of inherited bone marrow failure patients

artículo científico publicado en 2017

A multiparametric niche-like drug screening platform in acute myeloid leukemia

artículo científico publicado en 2022

Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?

artículo científico publicado en 2018

Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse.

artículo científico publicado en 2014

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment

artículo científico publicado en 2020

Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial

artículo científico publicado en 2014

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.

artículo científico publicado en 2018

Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype

scientific article published on 30 December 2019

Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy

artículo científico publicado en 2020

Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study

artículo científico publicado en 2011

Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis

artículo científico publicado en 2014

Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion

artículo científico publicado en 2015

Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

artículo científico publicado en 2011

Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)

artículo científico publicado en 2002

Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.

artículo científico publicado en 2014

Graft-Versus-Host Disease in Adolescents and Young Adults (15-24 Years Old) After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia in First Complete Remission

artículo científico publicado en 2016

High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.

artículo científico publicado en 2009

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

artículo científico publicado en 2015

Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia.

artículo científico publicado en 2014

Impact of the source of hematopoietic stem cell in unrelated transplants: comparison between 10/10, 9/10-HLA matched donors and cord blood

artículo científico publicado en 2015

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

artículo científico publicado en 2010

Intermediate maturation of Mycobacterium tuberculosis LAM-activated human dendritic cells

artículo científico publicado en 2007

Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA

artículo científico publicado en 2014

Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial

artículo científico publicado en 2012

PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome

scientific article published on 03 December 2018

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

artículo científico publicado en 2016

Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype

artículo científico publicado en 2005

Pyoderma gangrenosum of the breast: A diagnosis not to be missed ⬇️

artículo científico publicado el 18 de septiembre de 2010

Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group.

artículo científico publicado en 2015

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older

artículo científico publicado en 2012

TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.

artículo científico publicado en 2017

Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association

artículo científico publicado en 2009

Lista de obras de Nicolas Boissel

A landscape of germline mutations in a cohort of inherited bone marrow failure patients

A multiparametric niche-like drug screening platform in acute myeloid leukemia

Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?

Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse.

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment

Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.

Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype

Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy

Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study

Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis

Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion

Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)

Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.

Graft-Versus-Host Disease in Adolescents and Young Adults (15-24 Years Old) After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia in First Complete Remission

High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia.

Impact of the source of hematopoietic stem cell in unrelated transplants: comparison between 10/10, 9/10-HLA matched donors and cord blood

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

Intermediate maturation of Mycobacterium tuberculosis LAM-activated human dendritic cells

Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA

Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial

PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype

Pyoderma gangrenosum of the breast: A diagnosis not to be missed ⬇️

Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group.

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older

TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.

Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association